These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 28056809)

  • 1. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
    Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
    Burkard T; Kaiser CA; Brunner-La Rocca H; Osswald S; Pfisterer ME; Jeger RV;
    J Intern Med; 2012 Mar; 271(3):257-63. PubMed ID: 21726302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis.
    Kwok CS; Jeevanantham V; Dawn B; Loke YK
    Int J Cardiol; 2013 Aug; 167(3):965-74. PubMed ID: 22464478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
    Ayub A; Parkash O; Naeem B; Murtaza D; Khan AH; Jafri W; Hamid S
    Indian J Gastroenterol; 2016 Mar; 35(2):117-22. PubMed ID: 27056735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
    Serbin MA; Guzauskas GF; Veenstra DL
    J Manag Care Spec Pharm; 2016 Aug; 22(8):939-47. PubMed ID: 27459657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention.
    Nakayama A; Morita H; Ando J; Fujita H; Ohtsu H; Nagai R
    Heart Vessels; 2013 May; 28(3):292-300. PubMed ID: 22460241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major adverse cardiac events among postpercutaneous coronary intervention patients on clopidogrel and proton pump inhibitors.
    Ching GG; Li D; Baker WL; Hohl PK; Mather JF; McKay RG; Lundbye JB
    Conn Med; 2012 Apr; 76(4):205-11. PubMed ID: 22611719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.
    Banerjee S; Weideman RA; Weideman MW; Little BB; Kelly KC; Gunter JT; Tortorice KL; Shank M; Cryer B; Reilly RF; Rao SV; Kastrati A; de Lemos JA; Brilakis ES; Bhatt DL
    Am J Cardiol; 2011 Mar; 107(6):871-8. PubMed ID: 21247527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation.
    Schmidt M; Johansen MB; Robertson DJ; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Bøtker HE; Sørensen HT; Baron JA
    Aliment Pharmacol Ther; 2012 Jan; 35(1):165-74. PubMed ID: 22050009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
    Tran M; Tafreshi J; Pai RG
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators.
    Harjai KJ; Shenoy C; Orshaw P; Usmani S; Boura J; Mehta RH
    Circ Cardiovasc Interv; 2011 Apr; 4(2):162-70. PubMed ID: 21386091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review.
    Sherwood MW; Melloni C; Jones WS; Washam JB; Hasselblad V; Dolor RJ
    J Am Heart Assoc; 2015 Oct; 4(11):. PubMed ID: 26514161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis.
    Huang B; Huang Y; Li Y; Yao H; Jing X; Huang H; Li J
    Arch Med Res; 2012 Apr; 43(3):212-24. PubMed ID: 22564422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention.
    Lee D; Kim JS; Kim BJ; Shin SY; Kim DB; Ahn HS
    Medicine (Baltimore); 2021 Dec; 100(52):e27411. PubMed ID: 34967346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.
    Siller-Matula JM; Jilma B; Schrör K; Christ G; Huber K
    J Thromb Haemost; 2010 Dec; 8(12):2624-41. PubMed ID: 20831618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
    Bundhun PK; Huang F
    BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.